UNSPSC 51282109: Faropenem sodium

This classification denotes a beta-lactam antibiotic with the molecular formula C12H14NO5S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7O46G914RQ. European Medicines Agency schedules faropenem sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16432MIG. The term faropenem sodium is a U.S. FDA designation. Most nations schedule faropenem sodium under HS 29419000 and SITC 54139. As of Q4 2014, FAROPENEM SODIUM remains the US FDA Preferred Term for this commodity.

SMILES: CC(C1C2N(C1=O)C(=C(S2)C3CCCO3)C(=O)[O-])O.[NA+].

UNSPSC 51282109 Faropenem sodium is a Commodity code for a specific antibiotic pharmaceutical product. State and local government procurement activity under this code shows minimal recent engagement — the two most recent opportunities in the dataset are tagged to this code but do not involve faropenem sodium itself. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, totaling $2,999,999.11 over three years with 12-month initial and renewal terms. Seminole County, Florida issued an IFB for Naloxone and Safe Drug Deactivation Systems with quarterly delivery requirements. Both solicitations reflect state and county health departments procuring pharmaceuticals and medical supplies through cooperative purchasing frameworks or competitive sealed bids, but neither involves the specific active ingredient this code nominally describes.

The code shows activity concentrated in Florida and Illinois, though the dataset reflects a broader pattern of state and county health departments using cooperative purchasing vehicles and piggyback contracts for pharmaceutical supply. The Illinois opportunity (posted August 28, 2026, response due September 11, 2026) and Seminole County opportunity (posted June 30, 2026, IFB deadline July 26, 2023 — a historical post date) represent the only recent records. No current open solicitations specifically requesting faropenem sodium were identified in the source material. Vendors pursuing this code should note that state and local pharmaceutical procurement typically flows through consortium agreements like MMCAP Infuse and emphasizes lowest-price responsive bids, fixed-fee structures, and compliance with drug-free workplace, E-Verify, and federal environmental regulations when FEMA funding applies.